Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLG | P00747 | 2/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.47 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | APLNR | P35414 | 3/20 | 0.46 |
| ▸ | NMUR2 | Q9GZQ4 | 6/20 | 0.44 |
| ▸ | NMUR1 | Q9HB89 | 6/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GHSR | Q92847 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6176082 | 0.89 | RAMP3 (0.54) | NMUR2NMUR1 | |
| SCHEMBL6176075 | 0.84 | RAMP3 (0.52) | APLNR | |
| SCHEMBL30716923 | 0.81 | NMUR2 (0.51) | APLNRNMUR2NMUR1 | |
| SCHEMBL30716922 | 0.81 | NMUR2 (0.51) | APLNRNMUR2NMUR1 | |
| SCHEMBL29841738 | 0.81 | F2 (0.48) | F2APLNRNMUR2NMUR1 | |
| SCHEMBL27508582 | 0.81 | APLNR (0.51) | F2APLNRNMUR2NMUR1 | |
| SCHEMBL38657767 | 0.79 | NMUR2 (0.47) | F2APLNRNMUR2NMUR1 | |
| SCHEMBL29662094 | 0.79 | OPRM1 (0.46) | F2APLNRNMUR2NMUR1 | |
| SCHEMBL29488298 | 0.79 | OPRM1 (0.46) | F2APLNRNMUR2NMUR1 | |
| SCHEMBL31399622 | 0.79 | NRP1 (0.49) | F2NMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12128086-B2 | Formulations and methods of use for alpha connexin c-terminal (ACT) peptides | XEQUEL BIO, INC. (US) | 2024-10-29 | — | — | US | disclosed |
| US-20230263857-A1 | FORMULATIONS AND METHODS OF USE FOR ALPHA CONNEXIN C-TERMINAL (ACT) PEPTIDES | XEQUEL BIO, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11524049-B2 | Formulations and methods of use for alpha connexin c-terminal (ACT) peptides | XEQUEL BIO, INC. (US) | 2022-12-13 | — | — | US | disclosed |